Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Sep 07, 2022 2:05pm

86 Views

Post# 34947382

AGN.c featured on The Market Herald after sucessful study

The Market Herald recently featured Algernon Pharmaceuticals (AGN.c AGNPF) in 'The Power Play' after the biotech company reported positive drug study results.

Its Phase 2a Study evaluating its NP-120 for the treatment of idiopathic pulmonary fibrosis and chronic cough found statistically significant improvements in measures of cough.

The CEO of AGN Christopher J. Moreau, shares more details about these results and how they will positively impact the company here: https://pr.report/kxDignfG

AGN @ $6.45, MC $12.797M

<< Previous

Bullboard Posts

Next >>

Multi-bagger penny stock announces high-grade expansion